Key takeaways
- The peptide medicines with a weight-management use on their US labels include semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Saxenda), for people with obesity, or overweight with a weight-related condition, and setmelanotide (Imcivree) for rare genetic and hypothalamic obesity.
- The pivotal trials of semaglutide, tirzepatide and liraglutide were randomised, double-blind and placebo-controlled, in 1,961 to 3,731 adults followed for 56 to 72 weeks; their labels carry a boxed warning: the medicines caused thyroid C-cell tumours in rodents, and whether they do so in people is unknown.
- Orforglipron (Foundayo), approved in the US on 1 April 2026, acts on the same GLP-1 receptor but is a small molecule, not a peptide.
- Retatrutide, CagriSema and survodutide have published phase 3 trials and are investigational: none appeared in Drugs@FDA, the UK’s electronic medicines compendium or the TGA’s Product Information list on 18 November 2026.
- FDA says it has warned companies that illegally sold semaglutide, tirzepatide, retatrutide, survodutide and mazdutide products “falsely labeled ‘for research purposes’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.
01How do these compounds compare on approval and evidence?
Three tiers, dated 18 November 2026: approved medicines, drugs still in trials, and products sold online without approval. Approval is shown for the US, the UK and Australia. The study column gives the highest-tier study we found; tiers follow our evidence grades. This page does not cover compounds that act on growth hormone.
| Compound | Class | Approval: US · UK · Australia | Highest-tier study we found | Tier | What we don’t know |
|---|---|---|---|---|---|
| Semaglutide (Wegovy). Approved medicine | GLP-1 receptor agonist; a modified peptide | US: approved 4 Jun 2021 (Drugs@FDA) · UK: authorised (SmPC revised Sep 2026) · AU: TGA Product Information on file | STEP 1, NEJM 2021: randomised, double-blind, placebo-controlled; 1,961 adults without diabetes; 68 weeks | T1 | Whether the thyroid C-cell tumours it caused in rodents occur in people: the US label calls this unknown |
| Tirzepatide (Zepbound in the US, Mounjaro in the UK). Approved medicine | GIP and GLP-1 receptor agonist; a modified peptide based on the GIP sequence | US: Zepbound approved 8 Nov 2023 · UK: Mounjaro authorised, with weight management among its uses (SmPC revised 29 Aug 2026) · AU: TGA Product Information for Mounjaro on file | SURMOUNT-1, NEJM 2022: randomised, double-blind, placebo-controlled; 2,539 adults without diabetes; 72 weeks | T1 | The same rodent thyroid question, which its US label also calls unknown in people |
| Liraglutide (Saxenda). Approved medicine | GLP-1 receptor agonist; a modified peptide | US: approved 23 Dec 2014 · UK: authorised (SmPC revised Nov 2025) · AU: TGA Product Information on file | SCALE Obesity and Prediabetes, NEJM 2015: randomised, double-blind, placebo-controlled; 3,731 adults without type 2 diabetes; 56 weeks | T1 | The same rodent thyroid question, which its US label also calls unknown in people |
| Setmelanotide (Imcivree). Approved for rare forms of obesity only | MC4 receptor agonist; a cyclic peptide of 8 amino acids | US: approved 25 Nov 2020 · UK: SmPC on the emc · AU: no TGA Product Information found | Trial 1 on its US label: randomised, double-blind, placebo-controlled; 142 patients aged 4 and over with acquired hypothalamic obesity; 56 to 60 weeks | T1 | Anything outside the rare conditions on its label, which does not cover common obesity |
| Orforglipron (Foundayo). Approved medicine, not a peptide | GLP-1 receptor agonist; a small molecule | US: approved 1 Apr 2026 · UK: first authorised 10 Aug 2026 · AU: no TGA Product Information found | ATTAIN-1, NEJM 2025: randomised, double-blind, placebo-controlled; 3,127 adults with obesity and without diabetes; 72 weeks | T1 | Its thyroid C-cell tumour risk in people: the label carries a boxed warning on it and says the human relevance of the rodent tumours seen with this drug class “has not been determined”; rodent studies cannot show it, because orforglipron is not active in rats or mice |
| Retatrutide (Eli Lilly). In trials | GIP, GLP-1 and glucagon receptor agonist; a single peptide | Investigational, not an approved medicine. US: no application in Drugs@FDA · UK: MHRA, 15 Oct 2026, “has not been authorised” · AU: TGA, 5 Nov 2026, “has not been approved by the TGA or any comparable international regulator” | TRIUMPH-1, NEJM 2026: randomised, double-blind, placebo-controlled; 2,339 adults with obesity and without diabetes; 80 weeks | T1, investigational | Heart and kidney outcomes: TRIUMPH-Outcomes, about 10,000 adults, primary completion estimated Feb 2029 |
| CagriSema (cagrilintide with semaglutide; Novo Nordisk). In trials | Long-acting amylin analogue combined with a GLP-1 receptor agonist | Investigational. US: Novo Nordisk says it filed in Dec 2025, expects a decision in Q4 2026, and that CagriSema “is not approved” · UK: no emc entry · AU: no TGA Product Information found | REDEFINE 1, NEJM 2025: randomised, double-blind, placebo- and active-controlled; 3,417 adults without diabetes; 68 weeks | T1, investigational | FDA’s decision; heart outcomes: REDEFINE 3 is active, primary completion estimated Sep 2027 |
| Survodutide (Boehringer Ingelheim). In trials | Glucagon and GLP-1 receptor dual agonist | Investigational. US: no application in Drugs@FDA · UK: no emc entry · AU: no TGA Product Information found | SYNCHRONIZE-1, NEJM 2026: randomised, double-blind, placebo-controlled; 725 adults without diabetes; 76 weeks | T1, investigational | Whether any regulator will approve it |
| The same names sold online as research products. Sold without approval | Whatever the vial holds | US: FDA has warned sellers of semaglutide, tirzepatide, retatrutide, survodutide and mazdutide products “falsely labeled ‘for research purposes’” · UK: MHRA says retatrutide sold outside trials is “supplied illegally” · AU: TGA says a retatrutide product accessed outside a clinical trial “could be counterfeit” | None: no trial tested these products | Not graded: not the trial product | What any vial contains. A lab report covers only the tested sample |
| MOTS-c. Not an approved medicine | Mitochondrial-derived peptide, 16 amino acids | US: FDA staff say it is not a component of any FDA-approved drug · UK: no emc entry · AU: not named in the Poisons Standard (Oct 2026); we found no TGA statement applying any of its group entries to it and draw no scheduling conclusion of our own | Lee et al., Cell Metabolism 2015: male mice on a high-fat diet, 10 per group; a phase 2a trial in 120 adults (planned) is recruiting | T3 | Any effect in people: no published study has given it to people |
02Which peptides are approved for weight management, and how were they tested?
These are prescription medicines. Research-grade material sold online is not any of these medicines: it has not been through their trials, and no label covers it.
What the labels say they are for. The US labels for Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide) list use “to reduce excess body weight and maintain weight reduction long term” in adults with obesity, or with overweight and at least one weight-related condition, “in combination with a reduced calorie diet and increased physical activity” (Wegovy’s wording). Wegovy’s and Saxenda’s labels also cover some patients aged 12 and older. Wegovy’s label adds reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; Zepbound’s adds moderate to severe obstructive sleep apnoea in adults with obesity. Imcivree (setmelanotide) is limited to acquired hypothalamic obesity and to obesity caused by Bardet-Biedl syndrome or by POMC, PCSK1 or LEPR deficiency confirmed by genetic testing.
How they were tested. The pivotal trials were randomised, double-blind and placebo-controlled, in adults without diabetes who also received diet and activity counselling: STEP 1 for semaglutide (1,961 adults, 68 weeks, NEJM 2021), SURMOUNT-1 for tirzepatide (2,539 adults, 72 weeks, NEJM 2022) and SCALE Obesity and Prediabetes for liraglutide (3,731 adults, 56 weeks, NEJM 2015). Each measured the change in body weight and the share of people who lost at least 5% of it, against placebo. In each, body weight fell more with the medicine than with placebo; the size of the difference is in each label’s Clinical Studies section and in the papers. Each trial was funded by the medicine’s maker.
What the labels warn about. Wegovy, Zepbound and Saxenda carry a boxed warning: the active ingredient caused thyroid C-cell tumours in rodents, and it is unknown whether it does so in people. All three labels also warn about acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe gastrointestinal reactions, serious allergic reactions, and inhaling stomach contents during anaesthesia or deep sedation. Wegovy’s and Saxenda’s labels also warn about heart rate increase, and Wegovy’s and Zepbound’s about diabetic retinopathy complications in patients with type 2 diabetes. The most common adverse reactions they list are led by nausea, diarrhoea, vomiting and constipation. In STEP 1 and SURMOUNT-1, more people stopped treatment because of adverse events on the medicine than on placebo.
Setmelanotide. Imcivree’s US label describes a randomised, double-blind, placebo-controlled trial in 142 patients aged 4 and over with acquired hypothalamic obesity, 56 to 60 weeks long, measuring the change in body-mass index. Its label lists six warnings and precautions, all in its section 5; among them are depression and suicidal ideation, serious allergic reactions, skin darkening including darkening of existing moles, and two that apply in acquired hypothalamic obesity: acute adrenal insufficiency, and sodium imbalance in patients who also have central diabetes insipidus. Its most common adverse reactions include skin darkening, nausea, headache, diarrhoea and depression.
Orforglipron is not a peptide. Foundayo (orforglipron) acts on the GLP-1 receptor, but its phase 3 paper calls it “a small-molecule, nonpeptide” drug. FDA approved it on 1 April 2026, and its UK authorisation dates from 10 August 2026. ATTAIN-1 (NEJM, 2025) randomised 3,127 adults with obesity and without diabetes to orforglipron or placebo for 72 weeks; adverse events led more people to stop on orforglipron than on placebo. It is here because it acts on the same receptor as the peptides above.
03Which weight-management drugs are still in trials?
Investigational drugs, not approved medicines. We list who took part, what each trial measured and the adverse events reported.
Retatrutide is a single peptide that activates the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly. TRIUMPH-1 (NEJM, 2026) randomised 2,339 adults with obesity and without diabetes to retatrutide or placebo for 80 weeks. Its primary outcomes were the percentage change in body weight and, in sub-studies, a knee-pain score in 574 people with knee osteoarthritis and the apnoea–hypopnoea index in 243 people with obstructive sleep apnoea. The most common adverse events were gastrointestinal. Drugs@FDA lists no application for it, and the MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK.” More: the retatrutide guide.
CagriSema is Novo Nordisk’s investigational combination of semaglutide and cagrilintide, which the company calls “a long-acting amylin analog”. REDEFINE 1 (NEJM, 2025) randomised 3,417 adults without diabetes to CagriSema, semaglutide, cagrilintide or placebo for 68 weeks; its co-primary endpoints were the relative change in body weight and a reduction of 5% or more. Gastrointestinal adverse events affected 79.6% of people on CagriSema and 39.9% on placebo; the authors describe them as “mainly transient and mild-to-moderate in severity”. Novo Nordisk says it filed a New Drug Application with FDA in December 2025, that “A decision is expected in Q4 2026”, and that “CagriSema is not approved for use in the United States.” More: the cagrilintide guide.
Survodutide is Boehringer Ingelheim’s investigational glucagon and GLP-1 receptor dual agonist. SYNCHRONIZE-1 (NEJM, 2026) randomised 725 adults without diabetes, and SYNCHRONIZE-2 (NEJM, 2026) 752 adults with type 2 diabetes, to survodutide or placebo for 76 weeks; both measured the percentage change in body weight and a reduction of 5% or more. SYNCHRONIZE-CVOT (The Lancet, 2026) randomised 5,530 adults at raised cardiovascular risk to test whether survodutide was no worse than placebo on a composite of cardiovascular events, and reports that it met that test. In that trial serious adverse events were similar across groups, and gastrointestinal adverse events led to stopping treatment in 19.3% and 20.8% of the two survodutide groups against 1.9% on placebo.
FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says retatrutide and cagrilintide “cannot be used in compounding under federal law” and “have not been found safe and effective for any condition”.
04What is sold online as a peptide for weight loss, and what do regulators say?
Online, several of the drug names above, among them semaglutide, tirzepatide, retatrutide and survodutide, are also sold as “research” peptides, next to compounds that have only been studied in animals. Those products are not the medicines or the trial drugs described above.
FDA. FDA’s page on unapproved GLP-1 drugs says the agency “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.
MHRA. On 15 October 2026 the MHRA said that “Products being sold as retatrutide outside legitimate clinical trials are being supplied illegally and could pose serious risks to public health.”
TGA. On 5 November 2026 the TGA said that “Retatrutide is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator. Any retatrutide product accessed outside a clinical trial could be counterfeit and should not be used outside a clinical trial setting.”
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In the 2015 paper that described it, male mice on a high-fat diet (10 per group) were given MOTS-c, and the researchers measured weight gain and insulin response (T3). No published study has given it to people. A placebo-controlled phase 2a trial planned for 120 adults with prediabetes and overweight or obesity has been recruiting since February 2026; its primary measures are an insulin-sensitivity index and adverse events, and it has no results. Reviewing MOTS-c in 2026, FDA staff found “a lack of evidence to evaluate the effectiveness” for its nominated uses, which included obesity and “muscle/fat metabolism”, because the studies were “limited to in-vitro and in-vivo rodent models”. More: MOTS-c claims and the evidence.
A lab report shows what one tested sample contained. It cannot make that sample the product tested in a trial, or an approved medicine. Documented cases of products that did not match their labels: contamination and mislabeling.
05What we don’t know about peptides and weight loss
- Whether the thyroid C-cell tumours that semaglutide, tirzepatide and liraglutide caused in rodents occur in people. Their US labels call this unknown.
- Whether retatrutide, CagriSema or survodutide will be approved, and for what. Novo Nordisk expects an FDA decision on CagriSema in the fourth quarter of 2026.
- Their effects on heart and kidney outcomes. TRIUMPH-Outcomes (retatrutide) has an estimated primary completion of February 2029, and REDEFINE 3 (CagriSema) of September 2027.
- Whether MOTS-c has any effect in people. No published study has given it to people, and the one registered trial has no results.
- What a vial sold online contains. Only a test of that sample can say, and a test says nothing about effects.
Why we publish no doses for any of these compounds: why we don’t publish doses.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical or legal advice.